Capricor Therapeutics rises on meeting with US FDA for muscle disorder therapy

** Shares of therapy developer Capricor Therapeutics CAPR.O up 3.22% at $8.33 premarket

** Co says meeting with U.S. FDA has been scheduled to discuss regulatory path of its cell therapy for treatment of cardiomyopathy associated with Duchenne muscular dystrophy, which is type of muscle disorder

** To accommodate this meeting, co has rescheduled release of its Q2 results to August 11 from August 12

** FDA in July declined to approved Deramiocel, saying the therapy does not meet efficacy requirements and asked for more data

** Up to last close, stock down 41.5% YTD